iOnctura taps European syndicate for series A to bring two ‘best-in-class’ programs to the clinic

Created to house programs spun out from Merck KGaA and CRUK, iOnctura prepares for first-in-human studies

On the strength of its new €15 million ($16.6 million) series A round, iOnctura believes it can have two best-in-class oncology candidates in the clinic within a year.

Created in 2017 by former Merck KGaA (Xetra:MRK) executive Catherine Pickering in partnership with Cancer Research UK to house molecules spun

Read the full 485 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers